Key Points An improving U.S./China trading relationship could lift GE HealthCare's earnings outlook. The company is an exporter to China and also sources components from the country. These 10 stocks could mint the next wave of millionaires › A thawing in the U.S./China trading relationship is excellent news for a company like GE HealthCare Technologies(NASDAQ: GEHC). It's a large exporter to China (a market management sees as having excellent long-term potential) and uses Chinese-sourced components in its products. As such, the stock jumped as high as 11.3% in early trading on the news that the U.S. and China have agreed to ease tariffs on each other's goods for an initial 90-day period. What it means for GE HealthCare The impact of tariffs on GE HealthCare is seen in its earnings guidance. Back in February, management said tariffs would hit its earnings per share (EPS) in 2025 by $0.05. Fast forward to the end of April (almost a month after the "Liberation Day" tariffs were announced), and management discussed an additional $0.80 net hit from the tariffs. For reference, GE HealthCare's current full-year EPS guidance for 2025 calls for $3.90 to $4.10.Image source: Getty Images. In addition to a cost impact, GE HealthCare is a major exporter to China, and the country's aim to improve its healthcare provision is a key driver of demand for GE's scanners and imaging equipment. Indeed, management outlined that about $0.65 of the total $0.85 impact on EPS was due to U.S./China tariffs, with CFO James Saccaro noting on the earnings call: "It really goes both ways. We do ship a fair amount of product from the U.S. to China and vice versa." What's next for GE HealthCare? The thawing of the U.S./China trading relationship is excellent news for GE HealthCare and the Chinese healthcare system. It could also lead to investors pricing in improved assumptions for the company's earnings in 2025, which is why the stock is up today. Don’t miss this second chance at a potentially lucrative opportunity Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this. On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves: Nvidia:if you invested $1,000 when we doubled down in 2009,you’d have $302,503!* Apple: if you invested $1,000 when we doubled down in 2008, you’d have $37,640!* Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $614,911!* Story Continues Right now, we’re issuing “Double Down” alerts for three incredible companies, available when you joinStock Advisor, and there may not be another chance like this anytime soon. See the 3 stocks » *Stock Advisor returns as of May 12, 2025 Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends GE HealthCare Technologies. The Motley Fool has a disclosure policy. Here's Why GE HealthCare Stock Blasted Higher Today was originally published by The Motley Fool View Comments
Here's Why GE HealthCare Stock Blasted Higher Today
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...